Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC
June 22, 2022
Pasithea Therapeutics Corp. acquired all outstanding equity interests in Alpha-5 Integrin, LLC, a preclinical biotechnology company developing a monoclonal antibody targeting α5 integrin for ALS and other neuroinflammatory disorders. The transaction was valued at $3.75 million and was paid primarily in Pasithea common stock (3,260,870 shares) plus warrants; an entity controlled by Paul B. Manning was Alpha-5's majority owner prior to the deal.
- Buyers
- Pasithea Therapeutics Corp.
- Targets
- Alpha-5 Integrin, LLC
- Sellers
- An entity controlled by Paul B. Manning
- Industry
- Biotechnology
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
BioMarin Acquires Alesta Therapeutics
August 18, 2026
Biotechnology
BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, plus up to $215 million in development and regulatory milestone payments, to obtain its lead clinical-stage asset, ALE1. The acquisition closed on September 1, 2026; Alesta had spun out its non-ALE1 assets before closing, and became a wholly owned BioMarin subsidiary.
-
Warburg Pincus Acquires Integrace Private Limited
July 15, 2026
Pharmaceuticals
Warburg Pincus acquired 100% of Integrace Private Limited, a domestic orthopedics and gynecology-focused pharmaceutical formulations company, leading to full exits for existing shareholders True North Fund VI LLP and Temasek (via V-Science Investments). Industry veteran Rehan Khan was appointed CEO to lead Integrace’s next phase of growth as part of Warburg Pincus’ therapy-focused platform strategy.
-
AbbVie Completes $1.4B Acquisition of Aliada Therapeutics
December 11, 2024
Biotechnology
AbbVie completed its $1.4 billion cash acquisition of RA Capital Management portfolio company Aliada Therapeutics. The deal adds ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in Phase 1 for Alzheimer’s disease, and Aliada’s blood-brain barrier (BBB)-crossing MODEL delivery platform to AbbVie’s neuroscience pipeline.
-
Pasithea Therapeutics Acquires AlloMek Therapeutics
October 11, 2022
Biotechnology
Pasithea Therapeutics Corp. (Nasdaq: KTTA) acquired AlloMek Therapeutics, LLC, obtaining the preclinical MEK 1/2 inhibitor CIP-137401 to expand its CNS-focused drug-development pipeline. The deal closed on October 11, 2022 and included $1.05 million in upfront cash, issuance of restricted stock and warrants, plus potential clinical/regulatory milestones and royalties.
-
Sorrento Therapeutics Acquires ACEA Therapeutics
June 1, 2021
Biotechnology
Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.
-
Arcline Investment Management Acquires Polypeptide Therapeutic Solutions (PTS)
April 27, 2021
Biotechnology
Arcline Investment Management, a growth-oriented private equity firm, has acquired Polypeptide Therapeutic Solutions, S.L. (PTS) from Columbus Venture Partners. PTS is a Valencia-based GMP CDMO specializing in polyamino-acid (PAA) nanoparticle encapsulation and related drug-delivery services; Arcline plans to scale GMP production and expand the company's technology portfolio to support mRNA, gene/cell therapies, biologics and vaccines.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.